Current issue
Archive
Manuscripts accepted
About the Journal
Editorial office
Editorial board
Section Editors
Abstracting and indexing
Subscription
Contact
Ethical standards and procedures
Most read articles
Instructions for authors
Article Processing Charge (APC)
Regulations of paying article processing charge (APC)
OBSTETRICS AND GYNAECOLOGY / BASIC RESEARCH
Insights into the role of miR-877 and histidine-rich glycoprotein in preeclampsia
1
Department of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Ain Shams University, Cairo, Egypt
2
Department of Clinical Biochemistry, Faculty of Medicine, University of Jeddah, Jeddah, Saudi Arabia
3
Department of Medical Genetics, Faculty of Medicine, University of Jeddah, Jeddah, Saudi Arabia
4
Department of Biochemistry and Molecular Medicine, College of Medicine, Alfaisal University, Riyadh, Saudi Arabia
5
Department of Obstetrics and Gynecology, Faculty of Medicine, Ain Shams University, Cairo, Egypt
Submission date: 2023-11-25
Final revision date: 2024-06-29
Acceptance date: 2024-06-30
Online publication date: 2024-07-03
Corresponding author
Abeer Zakariyah
Department of Medical Genetics, Faculty of Medicine, University of Jeddah, 80327 Jeddah, Saudi Arabia
Department of Medical Genetics, Faculty of Medicine, University of Jeddah, 80327 Jeddah, Saudi Arabia
Arch Med Sci 2025;21(2):675-687
KEYWORDS
TOPICS
ABSTRACT
Introduction:
The clinical significance of miR-877 and histidine-rich glycoprotein (HRG) in preeclampsia (PE) remains unknown. Bioinformatics analyses have identified HRG as a target for numerous microRNAs. Based on novelty and target score, miR-877 was selected for this study to assess the clinical significance of miR-877 and HRG in placental and serum samples from patients with PE, with the aim of elucidating their potential role in disease progression.
Material and methods:
This study included 75 placental tissue samples and 75 serum samples obtained from patients with PE and normal controls. The PE group was subdivided into mild and severe cases. Relative quantification of miR-877 and HRG was performed using quantitative reverse transcriptase–polymerase chain reaction and enzyme-linked immunosorbent assay, respectively.
Results:
Placental and serum miR-877 levels were significantly elevated in pregnancies with PE, especially in severe cases, compared to normal controls. However, there were significant reductions in HRG serum levels along with significant increases in placental HRG levels among patients with PE. Moreover, significant differences in miR-877 and HRG levels were noted between the PE and control groups.
Conclusions:
miR-877 and HRG may play a role in the pathogenesis and progression of PE. Moreover, miR-877 potentially plays a role in the dysregulation of HRG. In addition, these molecules are potential biomarkers for the detection of PE as well as differentiation of mild and severe cases.
The clinical significance of miR-877 and histidine-rich glycoprotein (HRG) in preeclampsia (PE) remains unknown. Bioinformatics analyses have identified HRG as a target for numerous microRNAs. Based on novelty and target score, miR-877 was selected for this study to assess the clinical significance of miR-877 and HRG in placental and serum samples from patients with PE, with the aim of elucidating their potential role in disease progression.
Material and methods:
This study included 75 placental tissue samples and 75 serum samples obtained from patients with PE and normal controls. The PE group was subdivided into mild and severe cases. Relative quantification of miR-877 and HRG was performed using quantitative reverse transcriptase–polymerase chain reaction and enzyme-linked immunosorbent assay, respectively.
Results:
Placental and serum miR-877 levels were significantly elevated in pregnancies with PE, especially in severe cases, compared to normal controls. However, there were significant reductions in HRG serum levels along with significant increases in placental HRG levels among patients with PE. Moreover, significant differences in miR-877 and HRG levels were noted between the PE and control groups.
Conclusions:
miR-877 and HRG may play a role in the pathogenesis and progression of PE. Moreover, miR-877 potentially plays a role in the dysregulation of HRG. In addition, these molecules are potential biomarkers for the detection of PE as well as differentiation of mild and severe cases.
REFERENCES (49)
1.
Ramos JGL, Sass N, Costa SHM. Preeclampsia. Rev Bras Ginecol Obstet 2017; 39: 496-512.
2.
Rana S, Lemoine E, Granger JP, Karumanchi SA. Preeclampsia: pathophysiology, challenges, and perspectives. Circ Res 2019; 124: 1094-112.
3.
Weiler J, Tong S, Palmer KR. Is fetal growth restriction associated with a more severe maternal phenotype in the setting of early onset pre-eclampsia? A retrospective study. PLoS One 2011; 6: e26937.
4.
Stojanovska V, Scherjon SA, Plösch T. Preeclampsia as modulator of offspring health. Biol Reprod 2016; 94: 53.
5.
James JL, Whitley GS, Cartwright JE. Pre-eclampsia: fitting together the placental, immune and cardiovascular pieces. J Pathol 2010; 221: 363-78.
6.
Heilmann L, Rath W, Pollow K. Hemostatic abnormalities in patients with severe preeclampsia. Clin Appl Thromb Hemost 2007; 13: 285-91.
7.
Aksornphusitaphong A, Phupong V. Combination of serum histidine-rich glycoprotein and uterine artery Doppler to predict preeclampsia. Hypertens Res 2018; 41: 275-81.
8.
Bolin M, Åkerud P, Hansson A, Åkerud H. Histidine-rich glycoprotein as an early biomarker of preeclampsia. Am J Hypertens 2011; 24: 496-501.
9.
Williams VK, Griffiths AB, Carbone S, Hague WM. Fibrinogen concentration and factor VIII activity in women with preeclampsia. Hypertens Preg 2007; 26: 415-21.
10.
Halbmayer WM, Hopmeier P, Feichtinger C, Rubi K, Fischer M. Histidine-rich glycoprotein (HRG) in uncomplicated pregnancy and mild and moderate preeclampsia. Thromb Haemost 1992; 67: 585-6.
12.
Betel D, Wilson M, Gabow A, Marks DS, Sander C. The microRNA.org resource: targets and expression. Nucleic Acids Res 2008; 36: D149-53.
15.
Donker RB, Mouillet JF, Nelson DM, Sadovsky Y. The expression of Argonaute2 and related microRNA biogenesis proteins in normal and hypoxic trophoblasts. Mol Hum Reprod 2007; 13: 273-9.
16.
Liu M, Luo X, Gao L, Shi M, Zhou R, Wang T. Profiles of circular RNAs in human blood and their potential roles in preeclampsia. Arch Med Sci 2022. DOI: https://doi.org/10.5114/aoms/1....
18.
Macfarlane LA, Murphy PR. MicroRNA: biogenesis, function and role in cancer. Curr Genomics 2010; 11: 537-61.
19.
Skalis G, Katsi V, Miliou A, et al. MicroRNAs in preeclampsia. Microrna 2019; 8: 28-35.
20.
Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov 2017; 16: 203-22.
21.
Wang L, Li Y. MiR-29b-3p affects growth and biological functions of human extravillous trophoblast cells by regulating bradykinin B2 receptor. Arch Med Sci 2022; 18: 499-522.
22.
Zhang C, Han X, Wang X. Mechanisms underlying the improvement of preeclampsia through salvianolic acid B-regulated miRNA-155/CXCR4. Arch Med Sci 2023; 19: 430.
23.
Lip SV, Boekschoten MV, Hooiveld GJ, van Pampus MG, Scherjon SA, Plöschet T, et al. Early-onset preeclampsia, plasma microRNAs, and endothelial cell function. Am J Obstet Gynecol 2020; 222: 497.e1-497.e12.
24.
Luo S, Cao N, Tang Y, Gu W. Identification of key microRNAs and genes in preeclampsia by bioinformatics analysis. PLoS One 2017; 12: e0178549.
25.
Li S, Zhu Y, Liang Z, Wang X, Meng S, Xu X, et al. Up-regulation of p16 by miR-877-3p inhibits proliferation of bladder cancer. Oncotarget 2016; 7: 51773-83.
26.
Wu K, Yu Z, Tang Z, Wei W, Xie D, Xie Y, et al. miR-877-5p suppresses gastric cancer cell proliferation through targeting FOXM1. Onco Targets Ther 2020; 13: 4731-42.
27.
Ren M-H, Chen SI, Wang LG, Rui WX, Li P. LINC00941 promotes progression of non-small cell lung cancer by sponging miR-877-3p to regulate VEGFA expression. Front Oncol 2021; 11: 650037.
28.
ACOG Practice Bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet 2002; 77: 67-75.
29.
Sood R, Zehnder JL, Druzin ML, Brown PO. Gene expression patterns in human placenta. Proc Natl Acad Sci U S A 2006; 103: 5478-83.
30.
Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-54.
31.
Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001; 25: 402-8.
32.
Karrar SA, Hong PL. Preeclampsia. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023.
33.
Espinoza J, Vidaeff A, Pettker CM, Simhan H. ACOG practice bulletin, number 222 gestational hypertension and preeclampsia. Obstet Gynecol 2020; 135: e237-60.
34.
Kårehed K, Wikström AK, Olsson AK, Larsson A, Olovsson M, Åkerud H. Fibrinogen and histidine-rich glycoprotein in early-onset preeclampsia. Acta Obstet Gynecol Scand 2010; 89: 131-9.
35.
Bassiouny YA, El-Said MH, Mohamed NA, Dadoosh SF. The combination of histidine-rich glycoprotein and uterine artery doppler velocimetry in the prediction of pre-eclampsia. Evid Based Womens Health J 2016; 6: 9-13.
36.
Betoni JS, Derr K, Pahl MC, Rogers L, Muller CL, Packard RE, et al. MicroRNA analysis in placentas from patients with preeclampsia: comparison of new and published results. Hypertens Pregnancy 2013; 32: 321-39.
37.
Biró O, Alasztics B, Molvarec A, Joó J, Nagy B, Rigó J Jr. Various levels of circulating exosomal total-miRNA and miR-210 hypoxamiR in different forms of pregnancy hypertension. Preg Hypertens 2017; 10: 207-12.
38.
Poorolajal J, Jenabi E. The association between body mass index and preeclampsia: a meta-analysis. J Matern Fetal Neonatal Med 2016; 29: 3670-6.
39.
Sibai BM. Preeclampsia as a cause of preterm and late preterm (near-term) births. Semin Perinatol 2006; 30: 16-9.
40.
Liu Y, Li N, An H, Li Z, Zhang L, Li H, et al. Impact of gestational hypertension and preeclampsia on low birthweight and small-for-gestational-age infants in China: a large prospective cohort study. J Clin Hypertens (Greenwich) 2021; 23: 835-42.
41.
Chen M, Li Z, Cao L, Fang C, Gao R, Liu C. miR-877-3p inhibits tumor growth and angiogenesis of osteosarcoma through fibroblast growth factor 2 signaling. Bioengineered 2022; 13: 8174-86.
42.
Shamshirsaz AA, Paidas M, Krikun G. Preeclampsia, hypoxia, thrombosis, and inflammation. J Pregnancy 2012; 2012: 374047.
43.
Lee C, Dixelius J, Thulin Å, Kawamura H, Claesson-Welsh L, Olsson AK. Signal transduction in endothelial cells by the angiogenesis inhibitor histidine-rich glycoprotein targets focal adhesions. Exp Cell Res 2006; 312: 2547-56.
44.
Yin Y, Liu M, Yu H, Zhang J, Zhou R. Circulating microRNAs as biomarkers for diagnosis and prediction of preeclampsia: a systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol 2020; 253: 121-32.
45.
Fasoulakis Z, Kolialexi A, Mavreli D, Theodora M. MicroRNAs in preeclampsia. Expert Rev Mol Diagn 2023; 23: 1053-5.
46.
Mavreli D, Lykoudi A, Lambrou G, Papaioannou G, Vrachnis N, Kalantaridou S, et al. Deep sequencing identified dysregulated circulating microRNAs in late onset preeclampsia. In Vivo 2020; 34: 2317-24.
47.
Paulsen IW, Bzorek M, Olsen J, Grum-Schwensen B, Troelsen JT, Pedersen OB. A novel approach for microRNA in situ hybridization using locked nucleic acid probes. Sci Rep 2021; 11: 4504.
48.
Abdel Aty SM, El Sharawy BA, Abdel Maksoud S, Raafat E, Ghareeb MA. Plasma factor VII and histidine-rich glycoprotein as a potential markers in pre eclampsia. Egypt J Hosp Med 2018; 72: 4533-8.
49.
Nordqvist S, Kårehed K, Hambiliki F, Wånggren K, Stavreus-Evers A, Åkerud H. The presence of histidine-rich glycoprotein in the female reproductive tract and in embryos. Reprod Sci 2010; 17: 941-7.
Share
RELATED ARTICLE
| eISSN: | 1896-9151 |
| ISSN: | 1734-1922 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
